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Abstract
The majority of known human tumor-associated antigens derive from non-mutated self proteins. T
cell tolerance, essential to prevent autoimmunity, must therefore be cautiously circumvented to
generate cytotoxic T cell responses against these targets. Our strategy uses DNA fusion vaccines to
activate high levels of peptide-specific CTL. Key foreign sequences from tetanus toxin activate
tolerance-breaking CD4+ T cell help. Candidate MHC class I binding tumor peptide sequences are
fused to the C terminus for optimal processing and presentation. To model performance against a
leukemia-associated antigen in a tolerized setting, we constructed a fusion vaccine encoding an
immunodominant CTL epitope derived from Friend murine leukemia virus gag protein
(FMuLVgag) and vaccinated tolerant FMuLVgag-transgenic (gag-Tg) mice. Vaccination with the
construct induced epitope-specific IFN-γ-producing CD8+ T cells in normal and gag-Tg mice. The
frequency and avidity of activated cells were reduced in gag-Tg mice, and no autoimmune injury
resulted. However, these CD8+ T cells did exhibit gag-specific cytotoxicity in vitro and in vivo. Also,
epitope-specific CTL killed FBL-3 leukemia cells expressing endogenous FMuLVgag antigen and
protected against leukemia challenge in vivo. These results demonstrate a simple strategy to engage
anti-microbial T cell help to activate epitope-specific polyclonal CD8+ T cell responses from a
residual tolerized repertoire.
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Introduction
There is clear clinical evidence from recipients of allogeneic hematopoietic transplants that
CD8+ T cells reactive with leukemic cells can be curative [1]. To build on this success, passive
transfer of autologous, allogeneic or engineered CD8+ T cells against a range of target antigens
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is now being tested [2]. Such studies should provide proof of principle and validation of selected
targets, but the technical demands of this approach are high, and questions still remain regarding
the nature of the cell to be transferred and the ability of cells extensively expanded in vitro to
survive, divide, and migrate in vivo [2]. An alternative approach is to actively induce an immune
response in the tumor-bearing host, but the ability to achieve this has been questioned [3]. A
major obstacle derives from the limited capacity of patients to respond if the available repertoire
has been weakened by the processes of tolerance. However, the fact that cytotoxic CD8+ T
cells (CTL) can be induced in vitro against a range of normally expressed peptides, and that
these can kill tumor cells, suggests that deletional tolerance is incomplete in humans [4]. In
addition, there is clinical evidence that tumor-specific T cells can be induced in vivo against
self proteins, although whether the magnitude and avidity of the responses will be sufficient
to control tumor growth is less clear [5].
For candidate tumor antigens that are self proteins, it remains likely that the highest-avidity
cells have been deleted and the remaining potentially reactive repertoire is subject to peripheral
tolerance mechanisms [6-8]. Therefore, the challenge is to design vaccines that can overcome
the tolerogenic pressure on the residual repertoire. Once rescued from a tolerant state, it is
essential that these T cells, likely of intermediate or low avidity, can recognize and kill tumor
cells expressing the targeted antigen. Numerous vaccination strategies are being actively
pursued [9]. We have focused on genebased vaccines since they provide a flexible platform
for expressing antigens together with molecules able to direct and amplify immunity [10].
Clinical use of optimized DNA vaccines could follow from murine studies but translation to
human subjects has had to address two problems. The first was a concern that stimulation of
innate immunity via backbone CpG sequences might fail due to differences in expression of
TLR9 between mice and humans [11]. However, DNA vaccines retain immunogenicity in
TLR9-knockout mice [12], pointing to TLR9-independent pathways of immune activation.
The second obstacle reflected the dependence of transfection level on the volume injected,
which posed problems for scaling up from mice to human subjects [13-15]. Adequate antigen
levels are required especially at boosting, and difficulty in achieving high transfection
efficiencies could fail to boost responses in larger hosts [15]. To overcome these problems,
and to add an inflammatory stimulus, viral or bacterial vectors are being examined [16]. New
physical methods (e.g. electroporation) also appear to be effective and have the advantage,
compared to pathogen-based vectors, of not inducing blocking immunity against the vector
[13,14,17]. Electroporation is highly effective in large animals [18] and we are currently testing
it in the clinic, with no ill effects noted. Importantly, DNA vaccines appear safe, and, based
on their potential and safety profile, are now in pilot clinical trials [19,20]. We have developed
DNA fusion vaccines which encode two functional elements: one to stimulate CD4+ T cell
help using a microbial sequence, in our case a domain (DOM) of fragment C (FrC) from tetanus
toxin (TT), and the other consisting of a candidate tumor-specific MHC class I-binding peptide,
fused to the C terminus (p.DOM-peptide) [21]. The microbial component (DOM) was
minimized to reduce the potential for inclusion of immunodominant CTL epitopes that could
compete with the tumor-specific peptide [22]. Crucially, this design engages CD4+ T cells
from the non-tolerized anti-microbial repertoire. Induced responses against the fused MHC
class I-binding epitope were shown to depend on T cell help [23], a key requirement for the
induction and maintenance of effective CD8+ T cell immunity [24-26]. The ability of the cellular
machinery to dissect out candidate tumor epitopes from the backbone sequence of the encoded
antigen presents a limiting factor for presentation and immune induction [27]. We have
overcome this by cutting out the tumor-derived CTL epitope, placing it downstream of the
microbial DOM sequence to ensure optimal processing and presentation [27]. We have
demonstrated that this strategy activates high levels of epitope-specific CD8+ T cells and
establishes a durable memory response, leading to protective immunity in pre-clinical tumor
models [22,27-29]. These studies also revealed that it was possible to mobilize CD8+ T cells
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reactive with a male (H-Y)- specific epitope from a profoundly tolerized repertoire in male
mice [28]. However, the induced CD8+ T cells were unable to kill male splenocytes [28].
To model the performance of this strategy against a leukemia-associated antigen which is also
a self protein, we have focused on the immunodominant CTL epitope (gag85–93) derived from
the Friend murine leukemia virus (FMuLV) gag protein (FMuLVgag) expressed by FBL-3, an
FMuLV-transformed mouse leukemia [30,31]. Previously we generated a transgenic mouse
model in which FMuLVgag is expressed in the liver as a normal self protein (gag-Tg mice).
Tolerance to gag was evident from the fact that, in contrast to normal C57BL/6 (B6) mice,
“conventional” vaccination with FBL-3 tumor cells failed to generate a CD8+ T cell response
to FMuLVgag or to induce resistance to tumor [32]. In the current study, we used the tolerant
transgenic mice to assess the ability of a novel DNA fusion gene vaccine to induce effective
immunity against a tumor antigen that is also expressed by normal cells. For disseminated
leukemia, the goal can be limited to induction of CTL, since, once induced, CD8+ T cells should
be able to find and destroy accessible targets. Here we show that a DNA fusion vaccine
containing an epitope from the targeted tumor antigen and heterologous helper epitopes can
break tolerance and activate low-avidity gag85–93-specific CTL in mice expressing gag protein
as a self antigen, with no evidence of autoimmune injury. The induced CTL acquired cytotoxic
function in vivo and provided some protection against leukemia in vaccinated transgenic mice.
This model of continuous expression of a leukemia-associated antigen in normal tissues has
relevance for the clinic and reveals that DNA vaccination can activate surviving epitope-
specific CTL for focused immune attack against leukemic cells.
Results
Expression of gag RNA in liver and thymus of gag-Tg mice and leukemic cells
In the gag-Tg model the antigen is expressed not only in the liver but also in the thymus, leading
to tolerance in the CD8+ T cell repertoire [32,33]. However, the level of gag antigen expression
in these transgenic tissues compared to FBL-3 tumor cells is unknown. As a measure of
expression, we used quantitative RT-PCR (qRT-PCR). Surprisingly, both thymus and liver
biopsies from gag-Tg mice expressed higher levels of gag RNA compared to FBL-3 tumor
cells (about twofold and threefold, respectively) (Fig. 1). Although this is at the RNA level
only, it is indicative of higher levels of antigen expression. No amplification was detected in
control reactions lacking cDNA (data not shown). No gag transcript amplification was detected
using cDNA from EL4 cells or liver/thymus biopsies from WT mice (data not shown).
DNA vaccination induces gag85–93-specific CD8+ T cells in WT and gag-Tg mice
In order to investigate whether our vaccination strategy could overcome immune tolerance in
this model, we constructed a DNA fusion vaccine encoding the first domain (DOM) of FrC
from TT linked to the immunodominant H-2Db-restricted gag85–93 peptide (p.DOM-gag).
DNA vaccine design is indicated in Fig. 2. The ability of the p.DOM-gag DNA vaccine to
induce CD8+ T cell responses to gag85–93 was assessed by vaccinating WT and gag-Tg mice.
For comparison, control groups were immunized with irradiated FBL-3 cells, known to induce
a readily detectable protective CD8+ T cell response specific for the gag85–93 epitope in WT
mice [30,31]. T cell responses in the spleen were measured immediately ex vivo by ELISPOT
assay on day 36. Vaccination of B6 mice with p.DOM-gag induced gag85–93- specific T cell
responses as measured by ELISPOT assay for the production of IFN-γ (Fig. 3A), with
frequencies similar to those observed in FBL-3-vaccinated mice. The control DNA vaccine
(p.DOM) generated no gag85–93-specific responses (Fig. 3A). CD4+ Th cell responses against
the ‘promiscuous’ MHC class II binding peptide p30, embedded in the FrC domain (DOM),
were also detected in mice vaccinated with either DNAvaccine (p.DOMgag or p.DOM), but
not in mice immunized with irradiated FBL-3 cells, in which the low frequency of IFN-γ-
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producing cells detected was equivalent to background levels without peptide stimulation (Fig.
3A).
Gag-Tg mice were also tested for the ability to respond to the p.DOM-gag DNA vaccine. This
vaccine induced robust gag85–93- specific T cell responses, as monitored by the ex vivo IFN-
γ ELISPOT assay (Fig. 3B), although the frequency of responding cells was ~2.5-fold lower
than in WT mice (Fig. 3C). By contrast, immunization with irradiated FBL-3 tumor cells failed
to induce detectable gag85–93-specific T cell responses in gag-Tg mice (Fig. 3B), as previously
reported [32]. A non-specific background response of cells producing IFN-γ was observed in
mice after immunization with FBL-3, but this response was detected independent of stimulation
with any peptide. It may be the consequence of an inflammatory response resulting from the
injection of 1×107 irradiated tumor cells 8 days prior to obtaining the spleen, as a non-specific
response of similar strength was also observed in WT mice immunized with the cellular vaccine
(Fig. 3A).
The control p.DOM vaccine again induced no gag85–93-specific responses, although CD4+ Th
cell responses to the p30 peptide were detected in these animals, as well as those immunized
with p.DOM-gag (Fig. 3B). Since the CD4+ T cell response to p30 is derived from the
unmanipulated mouse repertoire, this was used as an overall indicator of the DNA vaccine
performance, which appeared effective in both WT and gag-Tg mice (Table 1). A survey of
larger numbers of individual mice was then carried out, which demonstrated that although
p.DOM-gag activated a lower frequency of gag85–93-specific T cells in gag-Tg mice compared
to WT mice (Fig. 3C), the number of animals responding was comparable between strains:
92% (12 of 13) of gag-Tg mice and 100% (11 of 11) of WT mice (Table 1). The efficacy of
the vaccine was further assessed by flow cytometric analysis to directly quantify the number
of gag85–93-specific CD8+ T cells present in splenic lymphocytes, using anti-IFN-γ
(intracellular) and anti-CD8 (surface) antibodies (Fig. 3D). Responses were again clearly
evident in WT and gag-Tg mice, and confirmed the lower frequency of responding cells in the
latter (Fig. 3D).
Avidity of induced gag85–93-specific CD8+ T cells in WT and gag-Tg mice
The frequency of gag85–93-specific cells elicited in gag-Tg mice is low compared to WT mice,
probably due to central and peripheral tolerance mechanisms which could potentially have
deleted a fraction of the repertoire, particularly the high-avidity gag85–93- specific CD8+ T
cells. To address the question of avidity, we compared the frequency of CD8+ T cells from
WT and gag-Tg mice that responded to varying concentrations of gag85–93 peptide in an IFN-
γ ELISPOT assay. WT and gag-Tg mice were vaccinated with either p.DOM-gag or the control
DNA vaccine and ELISPOT responses were measured at day 36, as described above.
Gag85–93-specific CD8+ T cells elicited in the gag-Tg mice had about tenfold lower avidity
compared to those from WT mice when tested against a range of gag85–93 peptide
concentrations ex vivo, with responses first detectable at 1 log higher peptide concentration
(0.01 lM vs. 0.001 lM) and peak responses attained at 1 log higher peptide concentration (1
lM vs. 0.1 lM) (Fig. 4). This difference, observed in two independent experiments comparing
12 gag-Tg and 11 WT mice, was reproducible and highly statistically significant (p≤0.001).
Cytotoxic activity in vitro of gag85–93-specific CD8+ T cells
The ability of the lower-avidity CD8+ T cell response induced by the p.DOM-gag DNA vaccine
in gag-Tg mice to exhibit lytic activity against targets expressing the gag85–93 epitope was
tested. At day 36 after vaccination, splenocytes from WT or gag-Tg mice were stimulated in
vitro with peptide for 6 days and lytic activity assessed in a 51Cr-release assay. CTL from either
WT or gag-Tg mice, primed with p.DOM-gag, lysed EL4 target cells pulsed with gag85–93
peptide but not a control peptide (Fig. 5A). CTL from either host also lysed FBL-3 leukemia
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cells expressing endogenous FMuLVgag antigen (Fig. 5A). No specific CTL activity was
generated by culture of splenocytes in vitro with gag85–93 peptide following vaccination with
the control vaccine, p.DOM, and no lytic activity was observed against the NK-susceptible cell
line YAC-1 (Fig. 5A).
Cytotoxic activity in vivo of gag85–93-specific CD8+ T cells
Clearly, gag85–93-specific lytic activity could be elicited following in vitro stimulation of
CD8+ T cells that had been induced in gag-Tg mice. However, it was unknown whether the
cells were capable of expressing such lytic activity within the in vivo tolerizing environment.
To address this, WT and gag-Tg mice were vaccinated with either p.DOM-gag, the control
DNA vaccine (p.DOM), or irradiated FBL-3 cells. At day 36, mice were injected intravenously
with sex-matched, syngeneic splenocyte targets pulsed with either gag85–93 peptide or control
peptide that had been differentially labeled with CFSE to permit distinction between the two
targets by flow cytometry. Twenty hours later, mice were sacrificed and the spleens analyzed
for persistence of CFSE-labeled targets. WT mice that had previously been vaccinated with
either p.DOM-gag or irradiated FBL-3 cells rapidly and efficiently lysed target splenocytes
pulsed with the gag85–93 peptide, as reflected by the clearance of >90% of the CFSEhi targets
by 20 h, but not those from the co-transferred population pulsed with the control peptide
(CFSElow) (Fig. 5B). Both populations of CFSE-labeled target cells survived in WT mice given
the control DNA vaccine, p.DOM (Fig. 5B).
Gag-Tg mice vaccinated with p.DOM-gag also specifically eliminated the gag85–93 peptide-
pulsed target cells (Fig. 5B). The specific lytic activity in gag-Tg mice immunized with this
DNA vaccine was slightly less than that observed in WT mice, but the difference did not reach
statistical significance (p=0.073; Fig. 5C). Thus, for target cells pulsed with high concentrations
of the peptide epitope, the reduced avidity of the CTL elicited in the transgenic mice did not
markedly affect their performance. In contrast to WT mice, gag-Tg mice vaccinated with
irradiated FBL-3 cells failed to lyse target cells labeled with the gag85–93 peptide (Fig. 5B and
C), confirming the inability of this approach to induce gag85–93-specific CTL in these animals.
Both populations of CFSE labeled target cells survived in gag-Tg mice that had received the
control DNA vaccine (Fig. 5B and C).
Induction of gag85–93-specific CTL by p.DOM-gag protects against FBL-3 leukemia growth
in vivo
Although the lower-avidity gag85–93-specific CTL induced in gag-Tg mice demonstrated the
ability to lyse peptide-pulsed targets in vivo, their capacity to recognize and protect mice from
leukemia in vivo was unknown. To address this, WT or gag-Tg mice were vaccinated with
p.DOM-gag or the control vaccine (p.DOM) and then challenged at day 36 by intraperitoneal
injection of 5×104 FBL-3 leukemia cells. Immunization with p.DOM-gag afforded significant
protection from leukemia in WT mice, with ~95% surviving, compared to naive animals or
those given the control vaccine (Fig. 6A). A low level of resistance (≤25%) was occasionally
observed in control WT groups, suggesting that injection of this dose of FBL-3 leukemia cells
alone can lead to the spontaneous induction of natural protective immunity in WT mice (Fig.
6A).
Vaccination with p.DOM-gag also led to significant protection in gag-Tg mice (Fig. 6B). In
these mice, there was no evidence for spontaneous induction of immunity following injection
of FBL-3 cells, since all naive or control-vaccinated mice succumbed by day 19 (Fig. 6B).
Thus, the lower-avidity gag85–93-specific CTL response induced in gag-Tg mice by the
p.DOM-gag vaccine is capable of mediating demonstrable protection from challenge with live
FBL-3 leukemia cells in vivo. However, this response appears suboptimal compared to the
responses elicited in WT mice, with only about one third of the gag-Tg mice vaccinated with
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p.DOM-gag exhibiting prolongation of survival (Fig. 6B). It is unclear whether this detectable
but reduced protection reflects primarily a qualitative or quantitative defect. One possibility is
that the response might be further amplified by adding novel adjuvants.
Assessment of autoimmunity in vaccinated gag-Tg mice
Despite the significant degree of protection against leukemia afforded by vaccination of gag-
Tg mice with p.DOM-gag, the presence of a population of activated gag85–93-specific CD8+
T cells following DNA immunization could potentially result in autoimmune injury to
hepatocytes expressing the FMuLVgag protein. To assess this, blood was drawn from gag-Tg
mice at day 36 following vaccination, and serum levels of the liver enzymes aspartate
aminotransferase and alanine aminotransferase measured as indicators of liver injury. Mice
were also sacrificed at this time point for blinded histological analysis of liver tissue. All
animals appeared healthy with no evidence of increased levels of aspartate aminotransferase
or alanine aminotransferase in the serum (data not shown). Histologic analysis of liver sections
in vaccinated gag-Tg animals indicated that all portal tracts were normal, with normal biliary
structures (Fig. 7). There was no inflammation in portal tracts or parenchyma, no hepatocyte
degeneration or loss, and the normal sinusoidal architecture was present (Fig. 7). No
autoimmune hepatocyte injury was evident, despite the relatively high levels of gag transcript
expression observed in gag-Tg liver compared to FBL-3 tumor cells (Fig. 1).
Discussion
Effective vaccination of patients with cancer using tumor-associated antigens has several major
problems to overcome. These include restrictions placed on the immune repertoire by
expression of the tumor antigen on normal tissues and the obstacles to activating the residual
repertoire to attack cancer cells and avoid autoimmunity.
The issue of tolerogenic pressure acting on the T cell repertoire has been widely investigated
in mouse models. The most common strategy has been to combine two transgenic strains
expressing either a targeted antigen or a T cell receptor (TCR) specific for an MHC class I-
associated peptide derived from the antigen. Although these studies are confined to assessing
the effects of antigen on a selected single-clonal T cell population, useful insights regarding
the obstacles to inducing T cell responses have been derived. Many models involve T cells
with high-affinity TCR, for which deletion is the usual outcome [34]. However, it is becoming
clear that low-avidity T cells can survive both central and peripheral tolerance mechanisms
provided that antigen expression is modest [7]. Development of autoimmune attack on tissues
expressing the target antigen appears to follow the same rules of dependence on level of
expression and T cell avidity [7]. Ideally, as is evident from clinical transplantation, the focus
should be on antigens that are highly expressed by tumor cells but weakly expressed by normal
cells.
A key challenge for the clinic is how best to activate the surviving lower-avidity T cells. In a
transgenic model in which influenza hemagglutinin (HA) is expressed in pancreatic islet β-
cells, low-avidity HA-specific CTL could be activated by immunization/infection with HA-
expressing virus [35]. Such CTL were capable of recognizing a tumor expressing high levels
of the HA antigen without injuring the pancreas. Further study of the fate of low-avidity
transgenic CD8+ T cells in this and a related model has revealed that the level of antigen is a
critical determinant, and that passively transferred CD8+ T cells ignored low levels of antigen
in normal pancreatic tissue, but could recognize higher levels of antigen expressed in malignant
pancreatic islet β-cells. However, these T cells exhibited limited anti-tumor activity unless
antigen-specific CD4+ Th cells were provided and both T cell subsets were activated together
by vaccination/infection with influenza virus [36].
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Unfortunately, the repeated use of viral vectors is not possible due to induction of blocking
immunity against viral proteins [37], a key disadvantage given that repeated vaccination is
likely to be required for cancer patients. Even if blocking antibody can be avoided, viral vectors
can lead to domination of the CTL hierarchy by virally derived epitope-specific responses, to
the detriment of immune induction against lower-affinity tumor-derived epitopes encoded
within the vaccine [38,39]. Considering these requirements, we have explored a DNA fusion
vaccine format that affords concurrent heterologous T cell help for effective CTL induction
in vivo, avoiding the use of viral vectors or adoptive transfer. The design focuses immunity
onto the encoded epitope and, when combined with electroporation at boosting, can achieve
high levels of CTL [14].
Using this strategy, our aim was to induce CTL against a model tumor antigen that was also a
self protein continually expressed in a large peripheral organ, but in which the T cell repertoire
was unmanipulated and therefore polyclonal, as this represents a typical setting for many
human cancers. We chose the gag-Tg mice since the antigen is mainly expressed in the liver,
but lower levels are detectable in the thymus, and there is clear evidence for tolerance [32,
33]. Furthermore, in a double-transgenic mouse expressing both gag in the liver and a TCR in
CD8+ T cells specific for the gag85–93 epitope [33], T cell numbers were reduced and those
remaining failed to proliferate or produce IL-2 in response to antigen [40]. Although our DNA
vaccine was operating within a polyclonal T cell repertoire, it is likely that it had to contend
with a similar combination of deletional and regulatory influences in the gag-Tg mice, and the
challenge was to activate the residual repertoire.
The DNA vaccine was able to mobilize an epitope-specific CD8+ T cell response capable of
proliferation, cytokine production, and killing of target FBL-3 leukemia cells in vitro and in
vivo. The provision of heterologous T cell help within the vaccine was aimed to circumvent
tolerance to tumor antigens, which may be more profound in the CD4+ T cell arm. Interestingly
the cellular vaccine failed to induce a detectable CD8+ T cell response against this dominant
epitope in the transgenic mice. Since the potential response is clear, the weakening of the
cellular vaccine is likely due to an inability to generate a tumor-derived CD4+ T cell response,
possibly due to the activity of Treg. It is known that effective CD4+ T cell help is critical for
inducing and maintaining an effective CTL response [24-26]. One question is whether true
tumor-specific T cell help might be required for long-term maintenance of CD8+ T cells [41].
In fact, our experience has been that challenge with tumor cells can expand tumor-specific
CD8+ T cells that have previously been primed by DNA fusion gene vaccination [27].
Nonetheless, we are investigating the effect on CD8+ T cell priming of also encoding tumor-
derived CD4+ T cell epitopes within our DNA vaccine and exploring the role of Treg. However,
the main point of our current study is that, in contrast to the cellular vaccine, the DNA fusion
vaccine is able to activate the residual CD8+ T cell repertoire and that these T cells can carry
out their effector functions in vivo.
Epitope-specific CTL appear able to kill target tumor cells effectively, although targeting
multiple epitopes might be even more potent [42], and avoid escape via epitope loss [43].
Vaccines encoding whole antigen cDNA appear to offer this potential, with the added
advantage of being suitable for all patients regardless of MHC class I haplotype. However,
placing an antigenic epitope at the C terminus of the FrC domain (DOM) promotes more
efficient induction of CD8+ T cells compared with using native cDNA [27], and
immunodominance argues against delivering multiple epitopes within the same vaccine
[44-46]. Instead, multiple vaccines could be used, each targeting a distinct tumor epitope, with
delivery of the second vaccine into a separate site to avoid competition [45,46]. This integrated
approach could compensate for the loss of T cell repertoire against individual epitopes.
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Following vaccination, the residual gag-specific CD8+ T cell repertoire surviving in the
tolerized mice clearly retain the capacity to kill tumor cells in vivo. Unfortunately, the highly
aggressive nature of the FBL-3 tumor makes it unsuitable to model therapeutic efficacy since
even a dose of 100 FBL-3 tumor cells per gag-Tg animal leads to death at day 12–14 (data not
shown). However, we have established previously that the vaccine design can be used
therapeutically, using a less aggressive tumor model that allows the immune system time to
respond to vaccination [14].
Once effector CTL are induced, the balance between tumor destruction and autoimmunity
depends at least in part on the relative levels of peptide expressed [7], and on the accessibility
of each target cell population to effector CTL infiltration [47]. Leukemic cells tend to be in
blood or lymphoid tissues and access to effector CTL seems assured. Our data indicate that in
this tolerance model, where expression of antigen in the thymus appears to cause deletion of
the repertoire [32,33], our DNA vaccine can activate residual gag-specific CTL able to lyse
leukemia cells exhibiting a relatively low level of gag transcript expression. The vaccine design
elicits no tumor-specific CD4+ T cells, thereby potentially protecting antigen-expressing
organs from entry of CTL, which is likely to depend on cytokine-producing CD4+ T cells at
the site [48]. Also, since these CD4+ T cells are targets for regulation, the vaccine may
circumvent suppression first by utilizing the microbial repertoire and then by evading tumor-
specific regulatory mechanisms. It is possible that the cellular vaccine containing irradiated
tumor cells could elicit CD4+ T cell responses, but this was not investigated due to the lack of
well-characterized gag-derived Th cell epitopes. For antigens expressed in the liver, there may
also be other factors operating, such as an intrinsic resistance of the liver to autoimmune
damage [32,47,49]. Previous attempts to promote autoreactivity in this model by combining
viral infection of the liver with transfer of gag-specific CTL were unsuccessful.
Control of tumor may require continuing surveillance by anti-tumor CTL. Once induced, their
ability to survive will be influenced by the level, mode and persistence of expression of tumor
antigen, together with the presence or absence of inflammatory mediators. Each model can
provide only a partial view, and the best test of performance of the DNA fusion vaccines will
therefore be in patients with cancer, with clinical trials now underway [21].
Materials and Methods
Cells
FBL-3 is a Friend virus-induced erythroleukemia of B6 origin that expresses FMuLV gag- and
env-encoded products and MHC class I molecules [50]. EL4 is a T cell lymphoma derived
from C57BL/6N mice, and YAC-1 is an NK-susceptible T cell lymphoma originating from
the A/Sn strain. All cells were maintained in RPMI 1640 medium supplemented with 10%
heat-inactivated FBS (Life Technologies, Paisley, UK), 1 mM sodium pyruvate, 2 mM L-
glutamine, non-essential amino acids (1% of 100x stock), 25 mM HEPES buffer and 50 μM
2-mercaptoethanol (complete medium).
Peptides
The H-2Db-restricted gag peptide gag85–93 derived from FMuLVgag (CCLCLTVFL) and the
FrC-derived Th peptide p30 (TT947–967; FNNFTVSFWLRVPKVSASHLE) have been
described previously [31,51]. Peptide controls included the H-2Db-restricted HY peptide
(WMHHNMDLI) derived from the Uty gene [52] and a TT-derived H-2Kb-restricted peptide
(SNWYFNHL) which is not encoded within these DNA vaccines [22]. Peptides were
synthesized commercially and supplied at >95% purity (PPRL, Southampton, UK).
Gag85–93 peptide stocks (5 mM) were dissolved in DMSO, and all other peptide stocks (1 mM)
were dissolved in water. Stocks were stored at −20°C.
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DNA vaccines
DNA vaccine design is indicated in Fig. 2. Construction of a DNA vaccine (p.DOM) containing
the gene encoding the first domain (DOM; TT865–1120, 256 amino acids plus leader sequence
of 19 amino acids) of FrC (TT865–1316) from TT has been described [22]. The p.DOM vaccine
was used as a template to construct p.DOM-gag, which encodes the immunodominant
H-2Db-restricted FMuLVgag CTL motif (gag85–93) fused to the C terminus of DOM. This was
achieved by PCR amplification of DOM using the forward primer 50-
TTTTAAGCTTGCCGCCACCATGGGTTGGAGC-3′ and the reverse primer 5′-
TTTTGCGGCCGCTTACAGAAAAACAGTCAAACAGAGACAACAGTTACCCCAGA
AGTCACGCAGGAA-3′, which fuses the gag85–93-encoding sequence to the 3′ terminus of
DOM. The resulting PCR fragment was cloned into the expression vector pcDNA3 (Invitrogen,
San Diego, CA). Both DNA constructs encode a leader sequence derived from the VH of the
IgM idiotype of the BCL1 tumor. DNA vaccine stocks were prepared and verified as previously
described [29].
Mice and vaccination protocol
The B6 gag-Tg model, in which the gag protein from FMuLV is expressed under the control
of the mouse albumin promoter in the liver, has been described previously [32,33,40]. For DNA
immunization, WT B6 or gag-Tg mice, bred in house, were vaccinated at 6–12 wk of age with
a total of 50 μg DNA in saline injected into two sites in the quadriceps muscles on day 0; mice
were anesthetized and administered booster injections together with electroporation at day 28,
as described previously [14]. For cellular immunization, mice were injected with 1×107
irradiated (10 000 rad) FBL-3 leukemia cells intraperitoneally on days 0 and 28. Animal
experimentation was conducted within UK Coordinating Committee for Cancer Research
(London, UK) guidelines, under Governmental license.
ELISPOT assay
Following priming (day 0) and booster injections (day 28), splenocytes were harvested on day
36 and vaccine-specific responses were assessed ex vivo by ELISPOT assay for IFN-γ secretion
(BD ELISPOT Set; BD PharMingen, San Diego, CA), as described previously [28].
Splenocytes were incubated with either the H-2Db-restricted gag85–93 peptide for 24 h to assess
CD8+ Tcell responses or the p30 peptide (derived from the FrC fusion domain, DOM) to assess
vaccine-induced CD4+ T cell responses. Triplicate wells were tested with a range of
gag85–93 peptide concentrations; control samples were incubated without peptide. The reducing
agent tris(2-carboxyethyl) phosphine hydrochloride (TCEP; Pierce Biotechnology, Rockford,
IL), which has been shown to enhance the antigenicity of cysteine-containing synthetic
peptides [53], was included in each microtiter well (200 μM) during the incubation stage, as
the gag85–93 epitope with three cysteines is otherwise very insoluble in vitro.
To compare the frequency of T cells responding to different concentrations of the gag85–93
peptide, as a measure of T cell avidity, baseline ELISPOT responses without peptide were
subtracted and the number of spot-forming cells (SFC)/million splenocytes calculated as a
percentage of the maximum SFC/million splenocytes for each individual mouse. The data were
pooled within each experimental group to calculate the mean ELISPOT response as a
percentage of the maximum response observed for each peptide concentration.
Generation and assay of gag85–93-specific CTL
To assess gag85–93-specific CTL responses, vaccinated mice were sacrificed at day 36 and
single-cell suspensions made from individual spleens in complete medium. Splenocytes were
washed and resuspended in 15 mL complete medium at 3×106 cells/mL, together with
recombinant human IL-2 (20 IU/mL; Perkin-Elmer, Foster City, CA), gag85–93 peptide (0.01
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μM) and 200 μM TCEP [53]. Following 6 days stimulation in vitro (37°C, 5% CO2), cytolytic
activity of the T cell cultures was assessed by standard 5-h 51Cr-release assay as previously
described [22], with target cells that were labeled with peptide/51Cr in the presence of 200
μM TCEP for 1 h at 37°C. Targets included EL4 cells pulsed with gag85–93 peptide or control
peptide (Uty), FBL-3 leukemia cells or NK-sensitive YAC-1 cells.
In vivo cytotoxicity assay
Splenocytes were harvested from WT and gag-Tg mice (2×107/mL in PBS) and cells from
each strain were pulsed with 5 μM gag85–93 peptide or control peptide (SNWYFNHL) for 30
min at 37°C in the presence of 200 μM TCEP and washed in PBS. The gag- and control peptide-
pulsed cells were then incubated with 5 μM or 0.5 μM CFSE (Molecular Probes, Invitrogen),
respectively, at room temperature for 8 min in the dark, and FBS (final concentration 20%)
was added to quench the labeling reaction. After washing, syngeneic cells were mixed together,
resuspended in PBS, and 2×107 cells in 0.1 mL injected intravenously to each sex-matched
syngeneic recipient. Splenocytes were harvested from individual recipients after 20 h and,
following lysis of RBC, cells expressing CFSE analyzed by FACSCalibur (BD Biosciences,
San Diego, CA).
Tumor challenge
Mice were challenged 8 days after the booster immunization (day 36 following priming) by
intraperitoneal injection of 5×104 FBL-3 leukemia cells in PBS. Mice were monitored daily
and euthanized on detection of tumor development, in accordance with UK Coordinating
Committee for Cancer Research guidelines.
Ex vivo intracellular IFN-γ assay
To assess priming of gag85–93-specific CD8+ T cells, mice were culled at day 36 following
immunization, and splenocytes processed for detection of intracellular IFN-γ. Viable
splenocytes were selected by density centrifugation and B cells removed using mouse pan B
DynabeadsJ (Invitrogen). Cells were incubated for 4 h at 37°C in 96-well plates (1×106 cells/
well) in complete medium together with 200 μM TCEP, 10 IU/well human recombinant IL-2,
1 μM gag85–93 peptide or control peptide (SNWYFNHL) and 1 μL/well Golgi Plug (BD
Biosciences). Following incubation, samples were processed to label surface CD8 and
intracellular IFN-γ, as previously described [27], and analyzed by FACSCalibur.
Analysis of autoimmune injury
Following priming (day 0) and booster vaccinations (day 28), groups of B6 and gag-Tg mice
were euthanized on day 36 to assess autoimmune injury. Control, naive groups received no
vaccinations. Liver samples were fixed in formaldehyde, paraffinembedded, sectioned and
stained with hematoxylin/eosin. Coded specimens were analyzed by a liver pathologist in a
blinded manner for inflammation and lymphocyte infiltration using a Zeiss Axioskop 2 MOT
microscope (Carl Zeiss, Oberkochen, Germany) and Zeiss Plan-NEOFLUAR 10x/0.30
objective lens. Images were recorded using a Zeiss AxioCam camera and Zeiss Axiovision 4
software with white balance correction provided by GNU Image Manipulation Program
(http://www.gimp.org) and processed with CorelDraw Graphics Suite 12 (Corel, Ottawa,
Canada).
Quantitative analysis of gag RNA expression
The FMuLVgag open reading frame encodes two alternative translational products: Pr65gag
and gPr75gag. The higher-molecular- weight protein gPr75gag has an additional 98-amino-acid
N-terminal signal sequence [54,55] within which the target immunodominant gag85–93 epitope
is located [31]. The major protein species generated in FBL-3 tumor cells is Pr65gag [32,54].
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The gag transgene present in gag-Tg mice was designed to optimize expression of only
gPr75gag [32,54].
To assess gPr75gag RNA expression, total RNA was extracted from FBL-3 cells, EL4 cells,
liver or thymus biopsies from gag-Tg and WT mice using RNeasy Plus mini kit (QIAGEN,
Valencia, CA). Total RNAwas reverse-transcribed using an oligo(dT) primer and a First-Strand
cDNA Synthesis kit (Amersham Pharmacia Biotech). The cDNA was used for all subsequent
qRT-PCR assays, using Taqman Universal PCR master mix (Applied Biosystems, Foster City,
CA) together with a primer/probe combination to detect either gPr75gag gene expression
(forward primer: 5′- GGCCGACTAGCTCTGTACCT- 3′; reverse primer: 50-
GGTGCACCAAAGAGTCCAA- 3′; probe 5′-FAM-CGGGTGTCTCGAACCCGTCA-
TAMRA-3′) or endogenous mouse β-actin gene expression (Applied Biosystems). The gag
primers were designed to only amplify product from gPr75gag, containing the gag85–93 epitope.
All reactions were performed in triplicate using the ABI PRISM 7500 Sequence detection
System (Applied Biosystems) according to the following thermal cycle protocol: 95°C for 10
min, followed by 40 cycles of 95°C for 15 s and 60°C for 90 s. The β-actin transcript level was
used to normalize gene expression levels.
Statistical analysis
Experimental groups were compared using an unpaired, two-tailed t-test. Survival curves were
compared using the χ2 log-rank test. Experimental groups were considered significantly
different from control groups if p<0.05.
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Figure 1.
Relative levels of gag RNA expression in FBL-3 tumor cells compared to liver and thymus
cells from gag-Tg mice. Total RNA was extracted from FBL-3 cells, thymus or liver biopsies
from gag-Tg mice; samples were isolated from either two independent FBL-3 cell cultures (#1,
#2) or two individual mice (#1, #2). Following cDNA synthesis, qRT-PCR was used to compare
the relative levels of gag gene expression between samples; qRT-PCR reactions were run in
triplicate for each sample and combined; error bars: SEM. -actin transcript amplification was
detected in all cDNA samples and was used to normalize gene expression levels.
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Figure 2.
Schematic diagram indicating DNA fusion vaccine design. The control vaccine p.DOM
contains the sequence encoding the N-terminal domain (DOM) of FrC from TT, including the
p30 CD4+ Th epitope. Sequence coordinates relative to the original TT sequence are indicated.
p.DOM-gag contains DNA sequence encoding the immunodominant H-2Db-restricted
gag85-93 CTL epitope derived from FMuLVgag ligated in-frame to the C terminus of DOM.
Each vaccine includes a leader sequence at the N terminus. Vaccine sequences were assembled
and inserted into the commercial vector pcDNA3 using Hind III and Not I restriction sites.
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Figure 3.
Ex vivo detection of gag-specific T cells in WT and gag-Tg mice following DNA vaccination.
WT and gag-Tg mice were immunized with p.DOM-gag or p.DOM DNA vaccines, or
irradiated FBL-3 cells, as indicated, on days 0 and 28; DNA booster injections at day 28 were
administered, together with electroporation. Splenocytes were harvested from individual mice
at day 36. (A, B) The numbers of SFC secreting IFN- were assessed ex vivo by ELISPOT assay.
Splenocytes were incubated with gag85-93 peptide to assess the epitope-specific CD8+ T cell
response, and with the p30 peptide to assess CD4+ T cell responses to the DOM component
of the vaccine. Test samples were set up in triplicate; baseline responses without peptides are
indicated. The data indicate mean SFC/million splenocytes and the SEM (error bars).
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Representative data from one of two identical experiments are shown. (C) The mean number
of gag85-93 epitope-specific SFC was compared between WT and gag-Tg mice. Responses to
1 M gag85-93 peptide were pooled from individual mice; data are expressed as mean SFC/
million splenocytes, together with the SEM. The number (n) of animals pooled per group is
indicated. (D) The frequency of gag85-93-specific CD8+ T cells producing IFN- was assessed
ex vivo by intracellular cytokine staining. Representative flow cytometric plots from individual
mice are shown (upper panel). Data were pooled from individual mice (lower panel) to indicate
the mean percentage of CD8+ T cells producing IFN- in response to gag85-93 peptide; error
bars: SEM.
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Figure 4.
DNA vaccination induces lower-avidity gag85-93-specific CTL in gag-Tg mice compared to
WT mice. WT and gag-Tg mice were immunized with p.DOM-gag on days 0 and 28; booster
injections at day 28 were administered, together with electroporation. Splenocytes were
harvested from individual mice at day 36 and the numbers of SFC secreting IFN- were assessed
ex vivo by ELISPOT assay. Splenocytes were incubated with varying concentrations of
gag85-93 peptide to assess the epitope-specific CD8+ T cell response; test samples were set up
in triplicate for each peptide concentration. Baseline responses without peptide were subtracted
and the number of SFC/million splenocytes was calculated as a percentage of the maximum
number of SFC/million splenocytes responding per mouse; data were then pooled for each
experimental group to calculate the mean ELISPOT response, together with the SEM (error
bars). Representative data from one of two identical experiments are shown.
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Figure 5.
DNA vaccination of gag-Tg mice induces gag85-93-specific effector CTL capable of in vitro
and in vivo cytolytic activity. WT and gag-Tg mice were immunized with p.DOM-gag or
p.DOM DNA vaccines, or irradiated FBL-3 cells, as indicated, on days 0 and 28. (A) At day
36, splenocytes were cultured with 0.01 M gag85-93 peptide for 6 days in vitro, prior to
measuring CTL activity by standard 51Cr-release assay. Targets were EL4 cells pulsed with
gag85-93 peptide or control peptide (Uty), FBL-3 leukemia cells expressing endogenous
FMuLVgag antigen, or the control cell line YAC-1. Representative data from individual mice
are shown; data from one of two identical experiments are shown; error bars: SEM. (B, C) At
day 36 following vaccination, mice were infused, by intravenous injection, with a 1:1 mixture
of target splenocytes: one population of cells had been pulsed with gag85-93 (gag) peptide while
the other had been pulsed with control (con) peptide (SNWYFNHL); each population was
labeled with a different concentration of CFSE (gag85-93 peptide: CFSEhi; control peptide:
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CFSElow). Splenocytes were harvested 20 h later and the frequency of each CFSE-labeled
target cell population determined by flow cytometric analysis. (B) Representative flow
cytometric profiles from individual mice. (C) The ratio of gag85-93- to control peptide-pulsed
cells surviving in each recipient was calculated. The ratios were normalized, by assuming that
the mean ratio was 1:1 in mice given the control vaccine (p.DOM), and pooled to calculate the
mean proportion of surviving donor cells pulsed with the gag85-93 peptide, together with the
SEM (error bars). Data are pooled from two of two identical experiments, each giving similar
results; the number (n) of animals pooled per group is indicated.
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Figure 6.
DNA vaccination of gag-Tg mice induces gag85-93-specific effector CTL able to protect mice
from FBL-3 leukemia. (A) WT and (B) gag-Tg mice were immunized with p.DOM-gag or
p.DOM DNA vaccines as indicated, on days 0 and 28; DNA booster injections at day 28 were
administered, together with electroporation. Naive (unimmunized) mice served as controls. At
day 36 mice were challenged by intraperitoneal injection of FBL-3 leukemia cells, and tumor
development monitored. Survival data in each panel are pooled from two of two identical
experiments, each giving similar results.
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Figure 7.
Absence of autoimmune liver injury following DNA vaccination of gag-Tg mice. Gag-Tg mice
were immunized with p.DOM-gag on days 0 and 28; DNA booster injections at day 28 were
administered, together with electroporation. Unimmunized mice served as naive controls. Mice
were euthanized at day 36 and liver samples were fixed in formaldehyde, paraffin-embedded,
sectioned and stained with hematoxylin/eosin. Representative sections from gag-Tg mice
immunized with p.DOM-gag (A) or naive gag-Tg controls (B) are shown; magnification, ×10.
Rice et al. Page 23
Eur J Immunol. Author manuscript; available in PMC 2009 December 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Table I
Ex vivo detection of vaccine-specific T lymphocytes in wt and gag-Tg mice by IFNγ ELISpot
assay.
Vaccine Peptide*
Vaccine-specific responses: †
wt mice gag-Tg mice
p.DOM-gag
gag85-93 11/11 (100%) 12/13 (92%)
p30 10/11 (91%) 13/13 (100%)
p.DOM
gag85-93 0/7 (0%) 0/8 (0%)
p30 7/7 (100%) 6/8 (75%)
Irradiated FBL-3
cells
gag85-93 10/10 (100%) 0/8 (0%)
p30 0/10 (0%) 0/8 (0%)
None
gag85-93 0/2 (0%) 0/3 (0%)
p30 0/2 (0%) 0/3 (0%)
*
Splenocytes incubated with 0.1μM gag85-93 peptide or 1μM p30 peptide.
†
Data presented as: number of positive responders/total mice tested (% responding).
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